Answers are grounded in this paper and cite their sources.
This conceptual analysis highlights business advantages of additive manufacturing in startups and established firms, suggesting its potential to improve supply chains and sustainability.
Three-dimensional (3D) printing has had extensive applications across many industries. This conceptual paper reviews evidence to articulate the business advantages of additive manufacturing (AM) and the contingencies that shape their realization. The findings across five advantage domains: (1) new venture creation and entrepreneurial agility; (2) cost, speed, and design-led value; (3) supply-chain resilience and digital inventory; (4) sustainable operations and localized production; and (5) emerging business models including 3D-Printing-as-a-Service (3DPaaS) and virtual warehousing. This paper proposes a framework that links venture stage and firm size to the appropriateness of AM use cases—rapid prototyping, bridge production, spare-parts fulfilment and low-volume end-use manufacturing—while highlighting enablers (DfAM, automation, and blockchain traceability) and constraints (economies of scale, qualification, IP/regulation). The analysis suggests that AM’s most robust business benefits arise when uncertainty is high, volumes are low-to-medium, customization is valued, and logistics or tooling costs dominate unit economics. Entrepreneurs benefit from reduced capital intensity and faster iteration; SMEs can internationalize digitally by offering on-demand, distributed production; and incumbents improve resilience via regionalized “print-near-use” networks and digital inventories of validated parts. It is concluded that with practical implications for managers and founders, a set of researchable propositions, and clear boundaries of generalization. While AM will not supplant high-volume conventional manufacturing, it is reshaping how value is created, captured and delivered in long-tail markets, spare-parts ecosystems, and innovation-intensive product categories.
No takes yet. Share an insight, caveat, or question.
Zulkefli et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: